FBR Capital Upgrades Alexion Pharmaceuticals (ALXN) to Market Perform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/23/2024
- Wall St gains on bright earnings, megacaps' support
- JPMorgan is worried about further S&P 500 sell-off potential
- Oil falls back after robust EU data as Mideast tensions linger
- China acquired top-end Nvidia AI chips despite recent US ban- Reuters
- SAP Q1 results fall short of Wall Street estimates as transformation kicks off
- Fisker (FSR) Appoints Michael Healy as Chief Restructuring Officer
- Kroger (KR), Albertsons and C&S Wholesale Grocers Announce an Updated and Expanded Divestiture Plan
- Costar Group (CSGP) to Acquire Matterport (MTTR) for $5.50/sh Cash and Stock
- Jaguar Health (JAGX) Files $75M Mixed Shelf
- Apple (AAPL) PT Lowered to $210 at Morgan Stanley, 'We'd buy post-earnings weakness'
- Apple, PepsiCo, JetBlue fall premarket; Amazon, GM and UPS rise
- After-hours movers: Cadence Design Systems, Cleveland-Cliffs, Riot Platforms, and more
- Midday movers: Tesla, Li Auto and CNH Industrial fall; Salesforce rises
- Midday movers: Netflix, Super Micro fall; Paramount Global gains
- After-hours movers: Netflix, Intuitive Surgical, Nordstrom, KB Home
Goldman Sachs Upgrades Alexion Pharmaceuticals (ALXN) to Buy
October 28, 2016 7:49 AM EDTGoldman Sachs upgraded Alexion Pharmaceuticals (NASDAQ: ALXN) from Neutral to Buy with a price target of $158.00.
For an analyst ratings summary and ratings history on Alexion Pharmaceuticals click here. For more ratings news on Alexion Pharmaceuticals click here.
Shares of Alexion Pharmaceuticals closed at $131.37 yesterday.
... MoreAlexion Pharma (ALXN) Tops Q3 EPS by 6c; Guides Relativity In-Line
October 27, 2016 6:35 AM EDTAlexion Pharma (NASDAQ: ALXN) reported Q3 EPS of $1.23, $0.06 better than the analyst estimate of $1.17. Revenue for the quarter came in at $799 million versus the consensus estimate of $786.86 million.
GUIDANCE:
Alexion Pharma sees FY2016 EPS at upper end of $4.50-$4.65, versus... More
Alexion Pharma (ALXN) Commences Two ALXN1210 Phase 3s
October 27, 2016 6:32 AM EDTAlexion Pharmaceuticals, Inc. (Nasdaq: ALXN) announced the initiation of two Phase 3 trials of ALXN1210, a highly innovative, longer-acting anti-C5 antibody that inhibits terminal complement. The first trial is a Phase 3 open-label, multinational, active-controlled study of ALXN1210 compared to eculizumab (Soliris®) in complement inhibitor treatment-naïve patients with paroxysmal nocturnal hemoglobinuria (PNH). Alexion has also accelerated the initiation of a registration trial of ALXN1210 in patients with atypical hemolytic uremic syndrome (aHUS). This second trial is a Phase 3, open-label, single arm, multinational trial to evaluate the safety and efficacy of ALXN1210 in complement inhibitor... More
